Fwd: Science X Newsletter Sunday, Sep 28

---------- Forwarded message ----------
From: Newsletter Phys.org <not-for-reply@physorg.com>
Date: Mon, Sep 29, 2014 at 2:24 AM
Subject: Science X Newsletter Sunday, Sep 28
To: Pascal Alter <pascal.alter@gmail.com>

Dear Pascal Alter,

Here is your customized Phys.org Newsletter for September 28, 2014:

Spotlight Stories Headlines

- MH370: Seabed images to support inch-by-inch plane search
- Post-Snowden, iPhone 6 encryption fans safety debate
- New mosquito-borne virus spreads in Latin America
- 'Cloaking' device uses ordinary lenses to hide objects across range of angles
- Quad Theatre: Cirque du Soleil's flying lampshades (w/ Video)
- Writers and readers go mobile and social at Wattpad
- 'Anti-Facebook' social network gets viral surge
- Human genome was shaped by an evolutionary arms race with itself
- Researchers identify early sign of pancreatic cancer

Astronomy & Space news

Russia successfully launches Proton-M rocket after accident Russia on Sunday successfully launched a Proton-M rocket carrying a satellite into orbit in the first such launch since one of the rockets fell back to Earth soon after liftoff in May.

Medicine & Health news

	New mosquito-borne virus spreads in Latin America (AP)—An excruciating mosquito-borne illness that arrived less than a year ago in the Americas is raging across the region, leaping from the Caribbean to the Central and South American mainland, and infecting more than 1 million people. Some cases have already emerged in the United States.
Researchers identify early sign of pancreatic cancer Scientists at Dana-Farber Cancer Institute, the Massachusetts Institute of Technology, and other institutions have discovered a sign of the early development of pancreatic cancer – an upsurge in certain amino acids that occurs before the disease is diagnosed and symptoms appear. The research is being published online today by the journal Nature Medicine.
	Virus probed in paralysis cases in 9 US kids (AP)—Health officials are investigating nine cases of muscle weakness or paralysis in Colorado children and whether the culprit might be a virus causing severe respiratory illness across the country.
Anamorelin improve appetite and body mass in patients with cancer anorexia-cachexia A new drug, anamorelin, improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.
Crizotinib treatment effective against ROS1-positive lung cancer Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene. In an article receiving Online First publication in the New England Journal of Medicine to coincide with a presentation at the European Society for Medical Oncology meeting, an international research team reports that crizotinib treatment led to significant tumor shrinkage in 36 of 50 study participants and suppressed tumor growth in another 9.
Countries must work together to stop organ traffickers, says researcher The author of new research into organ trafficking has called for a concerted international effort to confront the problem.
Cancer during pregnancy: Chemotherapy and radiotherapy are safe for babies, studies show Children who are exposed to chemotherapy or radiotherapy while in the womb suffer no negative impacts on mental or cardiac development, international studies presented at the ESMO 2014 Congress in Madrid have shown.
Rolapitant reduces nausea and vomiting in Phase III trial Rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to the results of a phase III trial presented for the first time today at the ESMO 2014 Congress in Madrid, Spain.
Afatinib improves progression-free survival in head and neck cancer The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show.
French studies measure benefits of colorectal cancer screening The introduction of biennial colorectal cancer screening in a region of France increased the rate of diagnosis of high risk pre-cancerous adenomas (sometimes called polyps) by 89%, researchers have reported at the ESMO 2014 Congress in Madrid.
Docetaxel or pemetrexed with cisplatin achieve comparable outcomes in non-squamous Lu Ca The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival, although docetaxel was associated with more frequent adverse events.
5 babies test positive for TB in Texas exposure (AP)—Five babies have tested positive for tuberculosis in West Texas after a nurse assistant at an El Paso hospital exposed hundreds of infants to the disease between September 2013 and last month.
Public versus private? Swiss mull health system shift Swiss voters were deciding Sunday whether to ditch the country's all-private health insurance system and create a state-run scheme, with polls indicating that they will reject the plan.
Ebola death toll passes 3,000: WHO The death toll in the world's worst-ever Ebola epidemic has now soared past 3,000, with the virus killing almost half of the more than 6,500 people it has infected, according to World Health Organization figures released Saturday.
Guyana, China sign five-year health pact China on Saturday agreed to train Guyanese doctors in medical specialities, as part of a five-year deal with the South American country.
Swiss reject switch from private to state health insurance Swiss voters on Sunday rejected a plan for a seismic shift from the country's all-private health insurance system to a state-run scheme.
1000 veterans line up for free marijuana (AP)—A marijuana giveaway for veterans attracted about 1,000 people to a Colorado hotel.

---

This email is a free service of Phys.org
You received this email because you subscribed to our list.
(......)
You are subscribed as pascal.alter@gmail.com